KEY TAKEAWAYS

Indian companies, like Chinese ones, have the expertise to handle small and large molecules, both of which are required to make antibody-drug conjugates
But China and Korea’s CDMOs have grown by leaps and bounds in the ADC space due to early investments, favorable policies, positive regulatory actions and a conducive innovation ecosystem
The global ADC market is expected to reach $65bn by 2030 at a compounded annual growth rate (CAGR) of 30%, according to Frost & Sullivan (F&S)
China accounts for 42% of the global ADC pipeline till November 2023
Among Indian majors, Sun Pharma has the only novel ADC in development while Zydus has developed a Kadcyla biosimilar for the domestic market
The others operate CRDMOs, with many of them bringing on additional capacities in 2024 (details in the story)
10 of the 15 ADCs across the world were approved and commercialized in the past five years
There is always scope to improve the safety profile and efficacy via new generation ADCs
India’s National Pharmaceutical Policy and National R&D Policy, funding via Production Linked Incentive Schemes, public-private partnerships could be key to novel drug development

Late To The Antibody-Drug Conjugate Party, But Will 2024 Be A Turning Point For India?

CDMO Capacity Expansion, Policy Push Are Positives